BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang H, Xu D, Li MT, Yao Y, Jin M, Zeng XF, Qian JM. Gastrointestinal manifestations on impaired quality of life in systemic sclerosis. J Dig Dis 2019;20:256-61. [PMID: 30838807 DOI: 10.1111/1751-2980.12720] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Gokcen N. PELVIC FLOOR MUSCLE EXERCISE AND PHYSICAL THERAPY MAY IMPROVE SYSTEMIC SCLEROSIS-ASSOCIATED FECAL INCONTINENCE. CAJMHE 2021;2:104-8. [DOI: 10.47316/cajmhe.2021.2.2.06] [Reference Citation Analysis]
2 Zampatti N, Garaiman A, Jordan S, Dobrota R, Becker MO, Maurer B, Distler O, Mihai C. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis. Arthritis Res Ther 2021;23:125. [PMID: 33888149 DOI: 10.1186/s13075-021-02506-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kaniecki T, Abdi T, McMahan ZH. Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis. Med Res Arch 2020;8:2252. [PMID: 34337149 DOI: 10.18103/mra.v8i10.2252] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Alian SM, Sherby NA, Sarhan SA. Cultural adaptation and validation of the Systemic Sclerosis Quality of Life questionnaire into Arabic language. Clin Rheumatol 2021;40:1409-16. [PMID: 32918142 DOI: 10.1007/s10067-020-05373-0] [Reference Citation Analysis]
5 Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics (Basel) 2020;10:E587. [PMID: 32823752 DOI: 10.3390/diagnostics10080587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hoffmann-vold A, Volkmann ER. Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. Journal of Scleroderma and Related Disorders 2021;6:37-43. [DOI: 10.1177/2397198319891282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]